AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Dupixent (dupilumab) is tipped to be the market ... strong performance in clinical trials improving atopic dermatitis (AD) in moderate-to-severe patients, where it is the first systemic drug ...

Dupixent is generally dosed every two or four weeks for AD. At the American Academy of Dermatology (AAD) congress in San Diego, data from STEAM-AD showed that amlitelimab achieved sustained ...

Filippos Maniatis, Healthcare Analyst at GlobalData, remarks, "With Dupixent setting the gold standard for AD, Sanofi has raised the bar for competitors in this space. However, Sanofi’s CEO has ...

“The anticipated sales of Dupixent for AD are projected to reach $6.2b in 2030, highlighting the significant rewards and substantial potential in this rapidly evolving market,” Maniatis added.

This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard. The use of Dupixent in AD has ...

Rinvoq's total estimated spending came in about $40 million behind Skyrizi's total last year, according to iSpot.TV, while Dupixent's total ... off on traditional TV advertising for its obesity ...

Dupixent (dupilumab) is a brand-name injection that’s prescribed for treating asthma. This article covers topics such as side effects, dosage, and how Dupixent works. Dupixent is available as a ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...